Literature DB >> 25083252

Curse of the ghost pills: the role of oral controlled-release formulations in the passage of empty intact shells in faeces. Two case reports and a literature review relevant to psychiatry.

Tongeji Elifazi Tungaraza1, Pravija Talapan-Manikoth2, Rosemary Jenkins2.   

Abstract

Orally taken tablets in different formulations continue to have a central role in the treatment of various psychiatric and medical conditions. In order to improve compliance, reduce the frequency of taking medications and minimize the peaks and troughs associated with certain immediate-release formulations, pharmaceutical companies have developed a number of novel methods of delivering oral solid dosage medications in the form of controlled-release (CR) formulations. Some CR formulations have been associated with pharmacobezoars and false-positive findings on certain physical investigations. Though CR drugs are commonly used in psychiatry, clinicians appear to have a limited understanding of how they are released for absorption once ingested. Some have insoluble parts that are excreted in faeces as 'ghost pills'. Due to lack of awareness of this phenomenon to both patients and the physicians, anxiety has ensued in some patients. Some clinicians have been puzzled or have been dismissive when faced with curious patients wanting to know more after they had observed tablet-like looking structures in faeces. We present two cases from our clinical setting and a few drawn from the World Wide Web to highlight the role of CR medications and their association with the ghost pill phenomenon. The mechanisms involved in drug release relevant to psychiatry medications are also briefly reviewed. The ghost pill phenomenon occurs with certain CR medications. This is a normal and expected outcome related to drug-release mechanisms of some of these products. It is inevitable that some patients will see what looks like tablets or capsules in faeces. Raising awareness of this phenomenon among clinicians would facilitate discussions and information sharing at the initial process of medication prescribing. Awareness among patients and carers would also help to allay anxiety.

Entities:  

Keywords:  Controlled release; Oxycontine; diffusion; drug release; ghost pill; osmotic release; venlafaxine

Year:  2013        PMID: 25083252      PMCID: PMC4110830          DOI: 10.1177/2042098612474681

Source DB:  PubMed          Journal:  Ther Adv Drug Saf        ISSN: 2042-0986


  16 in total

1.  A systematic review of the associations between dose regimens and medication compliance.

Authors:  A J Claxton; J Cramer; C Pierce
Journal:  Clin Ther       Date:  2001-08       Impact factor: 3.393

Review 2.  Clinical spectrum of the osmotic-controlled release oral delivery system (OROS), an advanced oral delivery form.

Authors:  Robert Conley; Suneel K Gupta; Gayatri Sathyan
Journal:  Curr Med Res Opin       Date:  2006-10       Impact factor: 2.580

Review 3.  Osmotically controlled drug delivery system with associated drugs.

Authors:  Brahma Prakash Gupta; Navneet Thakur; Nishi P Jain; Jitendra Banweer; Surendra Jain
Journal:  J Pharm Pharm Sci       Date:  2010       Impact factor: 2.327

Review 4.  Pharmacobezoars described and demystified.

Authors:  Serge-Emile Simpson
Journal:  Clin Toxicol (Phila)       Date:  2011-02       Impact factor: 4.467

5.  Gastrointestinal safety of an extended-release, nondeformable, oral dosage form (OROS: a retrospective study.

Authors:  Dorsey M Bass; Mary Prevo; Deborah S Waxman
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

6.  Oxycontin: the concept of a "ghost pill" and the postmortem tissue distribution of oxycodone in 36 cases.

Authors:  Daniel T Anderson; Kristina L Fritz; Joseph J Muto
Journal:  J Anal Toxicol       Date:  2002-10       Impact factor: 3.367

7.  Factors influencing compliance in schizophrenia patients.

Authors:  W Wolfgang Fleischhacker; Maria A Oehl; Martina Hummer
Journal:  J Clin Psychiatry       Date:  2003       Impact factor: 4.384

8.  Comparison of patient compliance with once-daily and twice-daily antibiotic regimens in respiratory tract infections: results of a randomized trial.

Authors:  Przemyslaw Kardas
Journal:  J Antimicrob Chemother       Date:  2007-02-08       Impact factor: 5.790

9.  Antihypertensive pharmacobezoar.

Authors:  L Michael Prisant; Vernon C Spaulding
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-04       Impact factor: 3.738

Review 10.  Oral drug delivery systems comprising altered geometric configurations for controlled drug delivery.

Authors:  Kovanya Moodley; Viness Pillay; Yahya E Choonara; Lisa C du Toit; Valence M K Ndesendo; Pradeep Kumar; Shivaan Cooppan; Priya Bawa
Journal:  Int J Mol Sci       Date:  2011-12-22       Impact factor: 5.923

View more
  8 in total

Review 1.  Drug Delivery Approaches in Addressing Clinical Pharmacology-Related Issues: Opportunities and Challenges.

Authors:  Hong Wen; Huijeong Jung; Xuhong Li
Journal:  AAPS J       Date:  2015-08-15       Impact factor: 4.009

2.  Linear and branched polymer prodrugs of the water-soluble nucleoside reverse-transcriptase inhibitor emtricitabine as structural materials for long-acting implants.

Authors:  Anika Shakil; Faye Y Hern; Chung Liu; Kartik Temburnikar; Pierre Chambon; Neill Liptrott; Tom O McDonald; Megan Neary; Andrew Owen; Caren Freel Meyers; Steve P Rannard
Journal:  J Mater Chem B       Date:  2022-06-15       Impact factor: 7.571

3.  Ghost-Pill-Buster: A Case Study of Intact Levetiracetam Extended-Release Tablets after Dissolution Testing.

Authors:  Dajun Sun; Hong Wen; Anna Externbrink; Zongming Gao; David Keire; Gregory Krauss; Wenlei Jiang
Journal:  CNS Drugs       Date:  2016-05       Impact factor: 5.749

Review 4.  A Clinician's Guide to Oral Extended-Release Drug Delivery Systems in Epilepsy.

Authors:  James W Wheless; Stephanie J Phelps
Journal:  J Pediatr Pharmacol Ther       Date:  2018 Jul-Aug

5.  Ghost tablet in feces.

Authors:  Masaya Iwamuro; Yosuke Morishita; Haruo Urata; Hiroyuki Okada
Journal:  J Gen Fam Med       Date:  2017-09-21

6.  Adherence, satisfaction, and experience with metformin 500 mg prolonged release formulation in Indian patients with type 2 diabetes mellitus: a postmarketing observational study.

Authors:  K M Prasanna Kumar; Manoj Chawla; Ami Sanghvi; Nadiminty G Sastry; Chaitanya Kotla; Sanjeev Phatak; Sanjay Choudhari
Journal:  Int J Gen Med       Date:  2019-04-09

7.  Measuring dissolution profiles of single controlled-release drug pellets.

Authors:  Heran C Bhakta; Jessica M Lin; William H Grover
Journal:  Sci Rep       Date:  2020-11-12       Impact factor: 4.379

8.  Ghost tablets mimicking intestinal parasite.

Authors:  Lorena Porte; Thomas Weitzel
Journal:  Braz J Infect Dis       Date:  2019-11-14       Impact factor: 3.257

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.